Understanding M&A Shareholder Rights Plans (Poison Pills) & Dilution Math
A Shareholder Rights Plan, colloquially known as a "Poison Pill", is a defensive corporate governance device adopted by a board of directors to prevent hostile acquisitions or creeping accumulations of stock in the public market. When adopted, the board issues one "Right" for each outstanding share of common stock. Initially, these rights are "dormant" and trade alongside the common stock, having no economic value or exercise power.
The Triggering Event: The "Acquiring Person"
The rights plan is triggered if an individual stockholder or coordinate group (the "Acquiring Person") acquires beneficial ownership exceeding a pre-established trigger threshold (typically 10% to 20%, with 15% representing the standard in Delaware corporations) without prior authorization from the board of directors. Once triggered, the rights separate from the common stock, certificates are distributed, and they become active exercise contracts.
The Flip-In Mechanism and Dilution Mathematics
Under the standard Flip-In Rights Plan, once a trigger occurs, each right (except those held by the Acquiring Person, which are explicitly voided) entitles its holder to purchase shares of the target's common stock at a major discount—almost always 50%.
The exercise terms allow the holder to pay the Exercise Price ($P_E$) and receive common shares having a market value equal to twice that exercise price ($2 \times P_E$). This formula yields a dramatic number of new shares issued per right, computed as:
Because the hostile acquirer is excluded from this massive discount purchase, their equity position is heavily diluted. If the target company has 10,000,000 shares, a hostile bidder acquires 1,600,000 shares (16%), and the exercise price is $150 while the market price is $50, the other shareholders can purchase 6 shares per right for $150. If 95% of the other shareholders participate, an additional 47,880,000 new shares are issued.
The hostile bidder's ownership percentage immediately crashes from 16.0% down to 2.72%. Furthermore, because the target receives substantial cash from the exercises ($1.2 billion in this example), the enterprise value jumps. However, the shear volume of new shares outstanding drives a diluted post-trigger share price. The bidder experiences a severe equity "haircut" (destruction of value) since their share counts remain unchanged while the market price is diluted.
The Board Exchange Option: Speed & Certainty
Most modern plans include a provision allowing the Board of Directors to simply "exchange" each outstanding Right (other than those of the Acquiring Person) for one share of common stock, without requiring shareholders to put up cash.
While the dilution factor is slightly lower than a full 50% discount cash-exercise, the Board Exchange Option is often preferred by directors because:
- Bypasses shareholder friction: It does not require shareholders to find cash to pay the exercise price, guaranteeing 100% execution of the dilution.
- Bypasses administrative complexity: Setting up a payment and collection system for millions of retail rights holders is administratively daunting.
- Avoids cash saturation: Sometimes boards do not want to flood the corporate treasury with billions of dollars of cash that they may have no immediate productive use for.
Delaware Legal Standards: Unocal & Revlon
Under Delaware law (which governs most US public companies), the adoption and maintenance of a poison pill is reviewed under specific fiduciary duty standards:
- The Unocal Standard (Unocal Corp. v. Mesa Petroleum Co., 1985): Because the board is defending the company, a "conflict of interest" is presumed. To protect themselves, directors must show: (1) they had reasonable grounds for believing there was a threat to corporate policy and effectiveness, and (2) the defense (the poison pill) was proportionate to the threat posed.
- Moran v. Household International, Inc. (1985): The Delaware Supreme Court officially confirmed that adopting a poison pill is a valid exercise of a board's authority under DGCL Section 157.
- The Revlon Standard (Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., 1986): If the board decides that a sale of the company is inevitable, their role shifts from "defenders" to "auctioneers." The poison pill can no longer be used to block bidders indefinitely; it must only be used to maximize the sale price for shareholders.